Toll-like receptors as targets for allergen immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 6, 2015, Pages 568-574

  Aryan, Zahra ^a   Rezaei, Nima ^b,c,d  

^a Student scientific research center   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK USERN   (Iran)

Author keywords

Adjuvants; Allergic rhinitis; Asthma; Food allergy; Pattern recognition receptors

Indexed keywords

1018 IMMNUOSTIMULATORY SEQUENCE; ALLERGEN; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; AZD 8848; CRX 675; PHOSPHORYL LIPID A; QBG 10; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VTX 1463; 1018 OLIGONUCLEOTIDE; ADENOSINE; AZD8848; CYT003-QBG10; LIPID A; OLIGODEOXYRIBONUCLEOTIDE; OLIGONUCLEOTIDE; PHENYLACETIC ACID DERIVATIVE; POLLINEX QUATTRO; VACCINE;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; CPG ISLAND; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ASTHMA; CLINICAL TRIAL (TOPIC); DESENSITIZATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES; RHINITIS, ALLERGIC;

ADENOSINE; ANIMALS; ANTI-ALLERGIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; LIPID A; MOLECULAR TARGETED THERAPY; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; PHENYLACETATES; RHINITIS, ALLERGIC; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84947025548     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000212     Document Type: Review

References (64)

1. Aryan Z, Compalati E, Canonica GW, et al. Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Rev Vaccines 2013;12:639-659.
2. Pfaar O, Demoly P, Gerth Van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854-867.
3. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneous. J Allergy Clin Immunol 2014;133:318-323.
4. Möbs C, Müller J, Rudzio A, et al. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy. Allergy 2015;70:715-719.
5. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med 2015;7:280s6-286s.
6. Gabler M, Scheiblhofer S, Kern K, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006;118:734-741.
7. Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014;164:46-63.
8. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011;11:702-712.
9. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012;32:294-325.
10. Srivastava KD, Siefert A, Fahmy T, et al. Investigation of peanut oral immunotherapy using CpG/peanut-nanoparticles in a murine model of peanut allergy. J Allergy Clin Immunol 2015;135: AB235.
11. Gamazo C, Gastaminza G, Ferrer M, et al. Nanoparticle based-immunotherapy against allergy. Immunotherapy 2014;6:885-897.
12. Casale TB, Kessler J, Romero FA. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:454-456.
13. Greiff L, Cervin A, Ahlstrom-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res 2012;13:53.
14. Horak F, Zieglmayer P, Zieglmayer R, et al. Intranasal toll-like receptor 8 agonist (VTX-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2011;127: AB199.
15. Gauvreau GM, Hessel EM, Boulet LP, et al. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174:15-20.
16. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009;15:410-416.
17. Ryu JH, Yoo JY, Kim MJ, et al. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways. J Allergy Clin Immunol 2013;131:549-561.
18. Golebski K, Luiten S, Van Egmond D, et al. High degree of overlap between responses to a virus and to the house dust mite allergen in airway epithelial cells. PloS One 2014;9:e87768.
19. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257-263.
20. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-364.
21. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130:1071-1082.
22. Carpenter S, O'Neill LA. Recent insights into the structure of Toll-like receptors and posttranslational modifications of their associated signalling proteins. Biochem J 2009;422:1-10.
23. Yang R-B, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharideinduced cellular signalling. Nature 1998;395:284-288.
24. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
25. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of singlestranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-1529.
26. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-(B by Toll-like receptor 3. Nature 2001;413:732-738.
27. Yamamoto M, Sato S, Hemmi H, et al. TRAM is specifically involved in the Tolllike receptor 4-mediated MyD88-independent signaling pathway. Nat immunol 2003;4:1144-1150.
28. Pone EJ, Lou Z, Lam T, et al. B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses. Autoimmunity 2015;48:1-12.
29. Zhuang H, Han S, Xu Y, et al. Toll-like receptor 7-stimulated tumor necrosis factor causes bone marrow damage in systemic lupus erythematosus. Arthritis Rheum 2014;66:140-151.
30. +CD25hiCD127lo/-natural regulatory T cells in human allergic asthma. Am J Respir Crit Care Med 2009;180:823-833.
31. Weigt H, Muhlradt PF, Emmendorffer A, et al. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003;207:223-233.
32. Tulic MK, Fiset PO, Manoukian JJ, et al. Role of toll-like receptor 4 in protection by bacterial lipopolysaccharide in the nasal mucosa of atopic children but not adults. Lancet 2004;363:1689-1697.
33. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
34. Sanati G, Aryan Z, Barbadi M, Rezaei N. Innate lymphoid cells are pivotal actors in allergic, inflammatory and autoimmune diseases. Expert Rev Clin Immunol 2015;11:885-895.
35. Nakata T, Yasuda M, Fujita M, et al. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cell Microbiol 2006;8:1899-1909.
36. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 2085-; 282:8.
37. Ghose C, Verhagen JM, Chen X, et al. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun 2013;81:2190-2196.
38. Sahoo BR, Basu M, Swain B, et al. Structural insights of rohu TLR3, its binding site analysis with fish reovirus dsRNA, poly I:C and zebrafish TRIF. Int J Biol Macromol 2012;51:531-543.
39. Tesse R, Pandey RC, Kabesch M. Genetic variations in toll-like receptor pathway genes influence asthma and atopy. Allergy 2011;66:307-316.
40. Heeg K, Dalpke A, Peter M, et al. Structural requirements for uptake and recognition of CpG oligonucleotides. Int J Med Microbiol 2008;298:33-38.
41. Groskreutz DJ, Monick MM, Powers LS, et al. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased doublestranded RNA responsiveness in airway epithelial cells. J Immunol 2006;176:1733-1740.
42. Wilson RH, Maruoka S, Whitehead GS, et al. The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nat Med 2012;18:1705-1710.
43. Page K, Ledford JR, Zhou P, et al. A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J Immunol 2009;183:3400-3408.
44. Yang H, Kong X, Wei J, et al. Cockroach allergen Per a 7 down-regulates expression of Toll-like receptor 9 and IL-12 release from P815 cells through PI3K and MAPK signaling pathways. Cell Physiol Biochem 2012;29:561-570.
45. Bauer RN, Diaz-Sanchez D, Jaspers I. Effects of air pollutants on innate immunity: the role of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors. J Allergy Clin Immunol 2012;129:14-24.
46. DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239-247.
47. Baldrick P, Richardson D, Wheeler AW. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 2001;20:737-743.
48. Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011;154:336-344.
49. Musarra A, Bignardi D, Troise C, et al. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria. A controlled field study. Eur Ann Allergy Clin Immunol 2010;42:115-119.
50. Rosewich M, Schulze J, Eickmeier O, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010;160:403-410.
51. Rosewich M, Schulze J, Fischer Von Weikersthal-Drachenberg KJ, et al. Ultrashort course immunotherapy in children and adolescents during a 3-yrs postmarketing surveillance study. Pediatr Allergy Immunol 2010;21:e185-e189.
52. Von Baehr V, Hermes A, Von Baehr R, et al. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol 2005;15:234-241.
53. Drachenberg KJ, Heinzkill M, Urban E, et al. Efficacy and tolerability of shortterm specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003;31:270-277.
54. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-1208.
55. Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505.
56. Scichilone N, Minaldi C, Santagata R, et al. Anti-inflammatory effects of preseasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics. J Asthma Allergy 2011;4:19-25.
57. Patel P, Holdich T, Fischer Von Weikersthal-Drachenberg KJ, et al. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 2014;133:121-129.
58. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235-241.
59. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweedtoll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-1455.
60. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-570.
61. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41:1305-1312.
62. Beeh KM, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013;131:866-874.
63. Horak F, Zieglmayer P, Zieglmayer R, et al. Intranasal Toll-like receptor 8 agonist (VTX-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2011;127: AB199.
64. Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs 2011;20:981-986.